Use of Depot Medroxyprogesterone Acetate Contraception and Incidence of Bone Fracture
Abstract
OBJECTIVE: Depot medroxyprogesterone acetate (DMPA) reversibly reduces bone mineral density. To estimate the extent to which DMPA might increase fracture risk, we undertook a retrospective cohort study of fractures in DMPA users and users of non-DMPA contraceptives, using the General Practice Research Database. METHODS: Eligible women were aged younger than 50 years at the qualifying first contraceptive prescription. The DMPA users were classified by DMPA exposure (cumulative and time of last dose) based on prescription records. All incident fractures were included; fracture incidence and risk factors before starting contraceptive use (DMPA or other) also were estimated. RESULTS: We identified 11,822 fractures in 312,395 women during 1,722,356 person-years of follow-up. Before contraceptive use started, DMPA users had higher fracture risk than nonusers (incidence rate ratio 1.28, 95% confidence interval [CI] 1.07-1.53). After DMPA started, crude fracture incidence was 9.1 per 1,000 person-years for DMPA users and 7.3 for nonusers (crude incidence rate ratio 1.23, 95% CI 1.16-1.30). Fracture risk in DMPA users did not increase after starting DMPA (incidence rate ratio after or before 1.08, 95% CI 0.92-1.26). There was little confounding by age or other factors that could be measured. Fracture incidence was 9.4 per 1,000 person-years in low-exposure DMPA users, and 7.8 per 1,000 in high-exposure DMPA users. The DMPA users had higher fracture risk than nonusers at the start of contraceptive use, with no discernible induction period. CONCLUSION: Although DMPA users experienced more fractures than nonusers, this association may be the result of confounding by a pre-existing higher risk for fractures in women who chose DMPA for contraception.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A large retrospective cohort study on more than 1.7 million women-years did not confirm an increased fracture risk in DMPA users.
“These results were not confirmed in a large retrospective cohort study on more than 1.7 million women-years [71].”
From Oral and depot progestin therapy for endometriosis: towards a personalized medicine (2017) · cites this paper as [71]
Cites
Smoothing and Differentiation of Data by Simplified Least Squares Procedures.
Savitzky, A., & Golay, M. J. E. (1964) · Analytical Chemistry · doi:10.1021/ac60214a047 · Cited by 21,904 · see citing works
Diagnosis of osteoporosis and assessment of fracture risk
Kanis, J. А. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08761-5 · Cited by 2,266 · see citing works
Effectiveness of Long-Acting Reversible Contraception
Winner, B., Peipert, J. F., Zhao, Q., Buckel, C. M., Madden, T. E., Allsworth, J. E., & Secura, G. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110855 · Cited by 1,153 · see citing works
Epidemiology of fractures in England and Wales
van Staa, T. P., Dennison, E. M., Leufkens, H. G. M., & Cooper, C. C. (2001) · Bone · doi:10.1016/s8756-3282(01)00614-7 · Cited by 1,132 · see citing works
Stone, K. L., Seeley, D. G., Lui, L., Cauley, J. A., Ensrud, K. E., Browner, W. S., Nevitt, M. C., & Cummings, S. R. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.11.1947 · Cited by 1,053 · see citing works
Validity of diagnostic coding within the General Practice Research Database: a systematic review
Khan, N., Harrison, S., & Rose, P. W. (2010) · British Journal of General Practice · doi:10.3399/bjgp10x483562 · Cited by 688 · see citing works
Validity of the General Practice Research Database
Jick, S. S., Kaye, J. A., Vasilakis‐Scaramozza, C., Rodríguez, L. A. G., Ruigómez, A., Meier, C. R., Schlienger, R. G., Black, C., & Jick, H. (2003) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.5.686.32205 · Cited by 584 · see citing works
Lasofoxifene in Postmenopausal Women with Osteoporosis
Cummings, S. R., Ensrud, K. E., Delmas, P. D., LaCroix, A. Z., Vukičević, S., Reid, D. M., Goldstein, S. R., Sriram, U., Lee, A., Thompson, J. R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0808692 · Cited by 386 · see citing works
Cromer, B. A., Blair, J. M., Mahan, J. D., Zibners, L., & Naumovski, Z. (1996) · The Journal of Pediatrics · doi:10.1016/s0022-3476(96)70148-8 · Cited by 241 · see citing works
The Impact of Lifestyle Factors on Stress Fractures in Female Army Recruits
Lappe, J. M., Stegman, M. R., & Recker, R. R. (2001) · Osteoporosis International · doi:10.1007/s001980170155 · Cited by 212 · see citing works
Injectable Hormone Contraception and Bone Density: Results from a Prospective Study
Scholes, D., LaCroix, A. Z., Ichikawa, L. E., Barlow, W. E., & Ott, S. M. (2002) · Epidemiology · doi:10.1097/00001648-200209000-00015 · Cited by 187 · see citing works
Surrogate End Points in Clinical Research: Hazardous to Your Health
Grimes, D. A., & Schulz, K. F. (2005) · Obstetrics and Gynecology · doi:10.1097/01.aog.0000157445.67309.19 · Cited by 154 · see citing works
Bone density recovery after depot medroxyprogesterone acetate injectable contraception use
Kaunitz, A. M., Arias, R., & McClung, M. R. (2008) · Contraception · doi:10.1016/j.contraception.2007.10.005 · Cited by 148 · see citing works
Self-citationKaunitz, A. M., Miller, P. D., Rice, V. M., Ross, D., & McClung, M. R. (2006) · Contraception · doi:10.1016/j.contraception.2006.03.010 · Cited by 118 · see citing works
Self-citationHarel, Z., Johnson, C. C., Gold, M. A., Cromer, B., Peterson, E., Burkman, R., Stager, M., Brown, R., Bruner, A., Coupey, S., et al. (2010) · Contraception · doi:10.1016/j.contraception.2009.11.003 · Cited by 100 · cited 1× · see citing works
“9% (femoral neck) were reported, with spine BMD returning to pre-exposure levels 60 weeks after discontinuation.(8) No evidence of reduced BMD was From RTI Health Solutions, Waltham, Massachusetts, and Research Triangle Park, North Carolina; the Michigan Bone & Mineral Clinic, Detroit, Michigan; the Department of Obst…”
BackgroundSelf-citationOrr‐Walker, B., Evans, M. C., Ames, R. W., Clearwater, J. M., Cundy, T., & Reid, I. R. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00582.x · Cited by 95 · see citing works
Use of Depot Medroxyprogesterone Acetate and Fracture Risk
Meier, C., Brauchli, Y. B., Jick, S. S., Kraenzlin, M. E., & Meier, C. R. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0032 · Cited by 90 · see citing works
Farr, S. L., Folger, S. G., Paulen, M. E., Tepper, N. K., Whiteman, M. K., Zapata, L. B., Culwell, K. R., Kapp, N., & Cansino, C. D. (2010) · Cited by 56 · see citing works
Vestergaard, P., Rejnmark, L., & Mosekilde, L. (2008) · Contraception · doi:10.1016/j.contraception.2008.07.014 · Cited by 51 · see citing works
Lasofoxifene in Postmenopausal Women With Osteoporosis
Cummings, S. R., Ensrud, K. E., Delmas, P. D., et al. (2010) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0b013e3181e5f28b · Cited by 25 · see citing works
Bone mineral density and DMPA.
Westhoff, C. L. (2002) · PubMed · Cited by 16 · see citing works
Johnson, C. C., Burkman, R. T., Gold, M. A., Brown, R. T., Harel, Z., Bruner, A. B., Stager, M., Bachrach, L. K., Hertweck, S. P., Nelson, A. L., et al. (2008) · Contraception · doi:10.1016/j.contraception.2007.11.002 · Cited by 15 · see citing works
Self-citationvan Staa, T. P., Abenhaim, L., Cooper, C. C., Zhang, B., & Leufkens, H. G. M. (2000) · Pharmacoepidemiology and Drug Safety · doi:10.1002/1099-1557(200009/10)9:5
Flagged first, then by citations
Cited by
Sorted by citations
U.S. Medical Eligibility Criteria for Contraceptive Use, 2016
Curtis, K. M., Tepper, N. K., Jatlaoui, T. C., Berry-Bibee, E., Horton, L. G., Zapata, L. B., Simmons, K. B., Pagano, H. P., Jamieson, D. J., & Whiteman, M. K. (2016) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6503a1 · Cited by 1,456 · see citing works
“Approximately 45% of all pregnancies that occur in the United States are unintended (1), with associated increased risks for adverse maternal and infant health outcomes (2) and increased health care costs (3).”
BackgroundBarra, F., Scala, C., & Ferrero, S. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1461840 · Cited by 100 · see citing works
Committee Opinion No. 602: Depot Medroxyprogesterone Acetate and Bone Effects
(2014) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000450758.95422.c8 · Cited by 107 · see citing works
Oral and depot progestin therapy for endometriosis: towards a personalized medicine
Buggio, L., Somigliana, E., Barbara, G., Frattaruolo, M. P., & Vercellini, P. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1381086 · Cited by 58 · see citing works
Modesto, W., Bahamondes, M. V., & Bahamondes, L. (2015) · Journal of Women's Health · doi:10.1089/jwh.2014.5077 · Cited by 36 · see citing works
Contraceptive considerations for women with gastrointestinal disorders
Sridhar, A., Cwiak, C. A., Kaunitz, A. M., & Allen, R. H. (2017) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4383-z · Cited by 6 · see citing works
Self-citation
- Authors
- Lanza, L. L., McQuay, L. J., Rothman, K. J., Bone, H. G., Kaunitz, A. M., Harel, Z., Ataher, Q., Ross, D., Arena, P. L., & Wolter, K. D.
- Affiliations
- Pfizer (United States) (US)
- Venue
- Obstetrics & Gynecology
- Published
- 2013-03
- Volume
- 121
- Issue
- 3
- Pages
- 593-600
- ISSN
- 0029-7844 (ISSN-L)
- OpenAlex
- W2017598716
- Cited by
- 78
- References
- 23
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 1 · 2022: 3 · 2021: 7 · 2020: 7 · 2019: 4 · 2018: 7 · 2017: 6 · 2016: 11 · 2015: 10 · 2014: 12 · 2013: 5
- FWCI
- 12.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Obstetrics and Gynecology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- depot medroxyprogesterone acetate, fracture risk, bone mineral density, hormonal contraception, osteoporosis, confounding by indication, fracture incidence, women
- MeSH terms
- Adolescent, Adult, Contraceptive Agents, Female, Delayed-Action Preparations, Female, United Kingdom, Humans, Middle Aged, Retrospective Studies, Incidence, Medroxyprogesterone Acetate, Fractures, Bone, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
